Skip to main content
OpenTrials
Completed

NCT Number: NCT01616693

Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines

Background: Strategies are needed to improve oral rotavirus vaccine (RV), which provides suboptimal protection in developing countries. Probiotics and zinc supplementation could improve RV immunogenicity by altering the intestinal microbiota and immune function.

This study enrolled infants 5 weeks old living in urban Vellore, India to assess the effects of daily zinc (5 mg), probiotic (1010 Lactobacillus rhamnosus GG) or placebo on the immunogenicity of two doses of RV (Rotarix,GlaxoSmithKline Biologicals) given at 6 and 10 weeks of age. Probiotics and zinc (or placebo) were provided for six weeks. A single dose of test product was administered daily one week prior to first study dose of rotavirus and polio vaccines through 1 week following second study dose of rotavirus and polio vaccines.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Immunity to Oral Rotavirus Vaccine Central Nervous System Diseases Central Nervous System Infections Enterovirus Infections Immunity to Oral Polio Vaccine Infections Myelitis Nervous System Diseases Neuroinflammatory Diseases Neuromuscular Diseases Picornaviridae Infections Poliomyelitis RNA Virus Infections Shedding of Oral Rotavirus Vaccine Spinal Cord Diseases Virus Diseases

Age range

5 week–16 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Christian Medical Center, Vellore

Vellore, Tamil Nadu, 632 004, India

About this study

Co- Primary objectives:

  • To evaluate the serologic immune response to rotavirus vaccine (sero-conversion or four-fold rise in rotavirus immunoglobulin A (IgA) antibodies) among Indian infants receiving zinc supplementation given daily for a week prior to the administration of the first dose through a week following the second dose of oral rotavirus vaccine compared to those receiving a zinc placebo.
  • To evaluate the serologic immune response to rotavirus vaccine (sero-conversion or four-fold rise in rotavirus IgA antibodies) among Indian infants receiving probiotic supplementation given daily for a week prior to the administration of the first dose through a week following the second dose of oral rotavirus vaccine compared to those receiving a probiotic placebo.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infants 35-41 days old
  • Live in area under surveillance
  • Current weight ≥3.2 kg
  • No syndromic evidence of immunocompromise as determined by medical doctor
  • No prior illness requiring hospitalization
  • No current medical condition as determined by medical doctor which precludes study involvement
  • Available for follow up for duration of study (through approximately 14 weeks of age)
  • Parents/guardians of infant are able to understand and follow study procedures and agree to participate in the study by providing signed informed consent

Exclusion criteria

  • Child has history of atopic symptoms
  • Child has a known digestive system defect
  • Child has history of chronic diarrhea
  • Child has major congenital anomalies
  • Child has received a prior dose of rotavirus vaccine
  • Child has received a prior dose of polio vaccine (beyond the birth dose)

Treatment and study plan

Probiotic

Dietary Supplement

A capsule that contains at least 1 x 10^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.

Other names: Culturelle

Zinc

Dietary Supplement

Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.

Probiotic placebo

Dietary Supplement

The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.

Zinc placebo

Dietary Supplement

The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.

Rotavirus vaccine

Biological

1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.

Other names: Rotarix®

Oral polio vaccine

Biological

A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.

Other names: Biopolio®

Primary outcomes

  1. Number/Percentage of Subjects With Immune Response to Rotavirus Vaccine

    Time frame: from first dose of rotavirus vaccine to 4 weeks after last dose of vaccine

    Defined as an increase in serum anti-rotavirus (RV) VP6 IgA antibodies consistent with seroconversion (detection of serum anti-RV VP6 immunoglobulin A (IgA) antibodies at a concentration ≥20 U/ml in a previously seronegative individual) or a fourfold rise in anti-RV VP6 IgA antibodies between baseline and 14 weeks of age.

    Pre-vaccination blood samples were taken when the subject received the first dose of rotavirus vaccine (when the subject was 6 weeks of age); post-vaccination blood samples were taken 4 weeks after the second dose of rotavirus vaccine was administered (14 weeks of age).

  2. Geometric Mean Concentration of Rotavirus-specific IgA

    Time frame: from first dose of rotavirus vaccine to 4 weeks after last dose of vaccine

    Pre-vaccination blood samples were taken when the subject received the first dose of rotavirus vaccine (when the subject was 6 weeks of age); post-vaccination blood samples were taken 4 weeks after the second dose of rotavirus was administered (14 weeks of age).

    Pre-vaccination blood samples were taken when the subject received the first dose of rotavirus vaccine (when the subject was 6 weeks of age); post-vaccination blood samples were taken 4 weeks after the second dose of rotavirus vaccine was administered (14 weeks of age).

Secondary outcomes

  1. Number/Percentage of Subjects With Immune Response to Trivalent Oral Poliovirus Vaccine (OPV)

    Time frame: from first dose of OPV to 4 weeks after last dose of OPV

    A serologic immune response to OPV is defined as a neutralizing antibody titer to polio virus subtype 3 greater than or equal to 1:8 at 14 weeks of age. This antigen will be used as a conservative estimate because it gives the lowest immune response of all three polio antigens.

    Pre-vaccination blood samples were taken when the subject received the first dose of OPV vaccine (when the subject was 6 weeks of age); post-vaccination blood samples were taken 4 weeks after the second dose of OPV was administered (14 weeks of age).

  2. Number/Percentage of Subjects Exhibiting Rotavirus Shedding in Stool After Dose 1

    Time frame: 0, 4 and/or 7 day post dose 1 of rotavirus vaccine

    Shedding of rotavirus following vaccination through detection of rotavirus antigen by ELISA and confirmed as vaccine type by Real-time polymerase chain reaction (RT-PCR). Stool samples were collected on Day 0 (i.e., day of vaccination or -1), Day 4 (±1) and Day 7 (-1 to +2) post vaccination.

  3. Number/Percentage of Subjects Exhibiting Rotavirus Shedding in Stool After Dose 2

    Time frame: 0, 4 and/or 7 day post dose 2 of rotavirus vaccine

    Shedding of rotavirus following vaccination through detection of rotavirus antigen by ELISA and confirmed as vaccine type by RT-PCR. Stool samples were collected on Day 0 (i.e., day of vaccination or -1), Day 4 (±1) and Day 7 (-1 to +2) post vaccination.

  4. Serious Adverse Events (SAEs)

    Time frame: from first day of study to 4 weeks after last dose

    Field workers documented information on SAEs through the duration of the study during home visits (twice weekly between study clinic visits) or SAEs were documented by study clinicians at the study clinic or hospital. All SAEs occurring at any time during the study were recorded on a SAE Form and were reviewed and evaluated by a study clinician and the local IRB. The relationship of the SAE to study vaccine was evaluated and recorded and reported to the local institutional review board (IRB). All SAEs were followed until satisfactory resolution.

Sponsors and collaborators

Lead sponsor

PATH

Other

Collaborators

  • Christian Medical College, Vellore, India
  • Ministry of Science and Technology, India

Registry information

Official study title

Supplementation With Zinc and/or Probiotics to Enhance the Immune Response of Oral Rotavirus and Polio Vaccines in Indian Infants

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Jun 12, 2012
Registry last updated
Dec 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.